Phase I Study of Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 06 Feb 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2021.
- 06 Feb 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
- 06 Feb 2017 Status changed from recruiting to active, no longer recruiting.